Foundry Healthcare DelCOL Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1JNJ | JOHNSON & JOHNSON | Healthcare | $609.12B | 49.04% |
2GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 13.42% |
3BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 9.99% |
4CI | CIGNA GROUP | Healthcare | $74.45B | 5.99% |
5IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 3.60% |
6TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $37.30B | 3.00% |
7ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 2.87% |
8VTRS | VIATRIS INC | Healthcare | $20.14B | 1.62% |
9ALGN | ALIGN TECHNOLOGY INC | Healthcare | $12.66B | 1.02% |
10TEM | TEMPUS AI INC | Healthcare | $9.42B | 0.76% |
11RGEN | REPLIGEN CORP | Healthcare | $8.31B | 0.67% |
12RYTM | RHYTHM PHARMACEUTICALS INC | Healthcare | $7.31B | 0.59% |
13LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.08B | 0.49% |
14AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $5.69B | 0.46% |
15VCYT | VERACYTE INC | Healthcare | $4.72B | 0.38% |
16TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.13B | 0.33% |
17OGN | ORGANON & CO | Healthcare | $3.55B | 0.29% |
18OPCH | OPTION CARE HEALTH INC | Healthcare | $3.41B | 0.27% |
19BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.83B | 0.23% |
20XRAY | DENTSPLY SIRONA INC | Healthcare | $2.81B | 0.23% |
21AGIO | AGIOS PHARMACEUTICALS INC | Healthcare | $2.36B | 0.19% |
22BHVN | BIOHAVEN LTD | Healthcare | $2.32B | 0.19% |
23NKTR | NEKTAR THERAPEUTICS | Healthcare | $2.31B | 0.19% |
24AGL | AGILON HEALTH INC | Healthcare | $2.17B | 0.17% |
25CDNA | CAREDX INC | Healthcare | $2.05B | 0.17% |
26ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $1.97B | 0.16% |
27AMLX | AMYLYX PHARMACEUTICALS INC | Healthcare | $1.97B | 0.16% |
28NEO | NEOGENOMICS INC | Healthcare | $1.90B | 0.15% |
29MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.15% |
30SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.15% |
31STOK | STOKE THERAPEUTICS INC | Healthcare | $1.81B | 0.15% |
32ZYME | ZYMEWORKS INC | Healthcare | $1.77B | 0.14% |
33HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.74B | 0.14% |
34TSHA | TAYSHA GENE THERAPIES INC | Healthcare | $1.71B | 0.14% |
35VIR | VIR BIOTECHNOLOGY INC | Healthcare | $1.59B | 0.13% |
36NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 0.13% |
37NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.11% |
38STAA | STAAR SURGICAL CO | Healthcare | $1.32B | 0.11% |
39ABSI | ABSCI CORP | Healthcare | $1.29B | 0.10% |
40INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.28B | 0.10% |
41COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $1.17B | 0.09% |
42WVE | WAVE LIFE SCIENCES LTD | Healthcare | $1.12B | 0.09% |
43USPH | U S PHYSICAL THERAPY INC | Healthcare | $1.12B | 0.09% |
44EYPT | EYEPOINT INC | Healthcare | $1.12B | 0.09% |
45BIOA | BIOAGE LABS INC | Healthcare | $1.01B | 0.08% |
46BVS | BIOVENTUS INC | Healthcare | $1.01B | 0.08% |
47AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $871M | 0.07% |
48REPL | REPLIMUNE GROUP INC | Healthcare | $859M | 0.07% |
49SIBN | SI-BONE INC | Healthcare | $771M | 0.06% |
50CADL | CANDEL THERAPEUTICS INC | Healthcare | $746M | 0.06% |
51CLYM | CLIMB BIO INC | Healthcare | $727M | 0.06% |
52EVH | EVOLENT HEALTH INC | Healthcare | $654M | 0.05% |
53MYGN | MYRIAD GENETICS INC | Healthcare | $584M | 0.05% |
54STTK | SHATTUCK LABS INC | Healthcare | $577M | 0.05% |
55CTNM | CONTINEUM THERAPEUTICS INC | Healthcare | $532M | 0.04% |
56ZURA | ZURA BIO LTD | Healthcare | $518M | 0.04% |
57ARVN | ARVINAS INC | Healthcare | $517M | 0.04% |
58DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $517M | 0.04% |
59RGNX | REGENXBIO INC | Healthcare | $511M | 0.04% |
60SGMT | SAGIMET BIOSCIENCES INC | Healthcare | $479M | 0.04% |
61PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.04% |
62KYTX | KYVERNA THERAPEUTICS INC | Healthcare | $453M | 0.04% |
63BNTC | BENITEC BIOPHARMA INC | Healthcare | $439M | 0.04% |
64CCRN | CROSS COUNTRY HEALTHCARE INC | Healthcare | $428M | 0.03% |
65ASMB | ASSEMBLY BIOSCIENCES INC | Healthcare | $426M | 0.03% |
66CBIO | CRESCENT BIOPHARMA INC | Healthcare | $407M | 0.03% |
67STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.03% |
68ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.03% |
69LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $311M | 0.03% |
70ZSQR | Z SQUARED INC | Healthcare | $260M | 0.02% |
71QTTB | Q32 BIO INC | Healthcare | $255M | 0.02% |
72SRZN | SURROZEN INC | Healthcare | $255M | 0.02% |
73SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.02% |
74KROS | KEROS THERAPEUTICS INC | Healthcare | $211M | 0.02% |
75AGEN | AGENUS INC | Healthcare | $209M | 0.02% |
76DTIL | PRECISION BIOSCIENCES INC | Healthcare | $203M | 0.02% |
77AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.02% |
78DERM | JOURNEY MEDICAL CORP | Healthcare | $197M | 0.02% |
79INGN | INOGEN INC | Healthcare | $178M | 0.01% |
80ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.01% |
81RCEL | AVITA MEDICAL INC | Healthcare | $157M | 0.01% |
82JYNT | JOINT CORP | Healthcare | $127M | 0.01% |
83CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.01% |
84OPRX | OPTIMIZERX CORP | Healthcare | $126M | 0.01% |
85SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $120M | 0.01% |
86VRCA | VERRICA PHARMACEUTICALS INC | Healthcare | $96M | 0.01% |
87CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.01% |
88ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.01% |
89CLNN | CLENE INC | Healthcare | $76M | 0.01% |
90AGPU | AXE COMPUTE INC | Healthcare | $72M | 0.01% |
91LNSR | LENSAR INC | Healthcare | $70M | 0.01% |
92SNWV | SANUWAVE HEALTH INC | Healthcare | $55M | 0.00% |
93XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.00% |
94MCRB | SERES THERAPEUTICS INC | Healthcare | $52M | 0.00% |
95TIL | INSTIL BIO INC | Healthcare | $50M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $1.24T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 97% toward Large, 39% toward Growth. +3% unclassified (12 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual41.6%Margin-33.4%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual49.0%Margin-24.0%
At least 50% of total assets must sit in cash, government securities, other RICs, and other securities limited to 5% of assets and 10% of the issuer's voting securities per issuer.
Required>= 50.0%Actual41.6%Margin-8.4%Arithmetically entailed by '40 Act 5(b)(1) diversification (75%/5% asset leg) — it cannot fail independently, so it is reported outside the tally rather than counted as a separate check.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 45.0% | -6.9% |
| 3 yearsp.a. | 3.9% | -17.0% |
| 5 yearsp.a. | -0.6% | -12.8% |
| 10 yearsp.a. | 6.5% | -10.3% |
| Since inceptionp.a. | 5.5% | -8.0% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 16.8% | 3.9% |
| 2025 | 12.8% | -23.0% |
| 2024 | -5.3% | -9.7% |
| 2023 | -11.8% | -28.2% |
| 2022 | -7.2% | 10.5% |
| 2021 | 3.8% | -24.3% |
| 2020 | 29.9% | 3.6% |
| 2019 | 19.8% | -11.4% |
| 2018 | 8.8% | 4.0% |
| 2017 | 14.3% | -11.0% |
| 2016 | 3.8% | 5.7% |
| 2015 | 16.3% | 1.9% |
| 2014 | 22.3% | -3.8% |
| 2013 | 29.8% | -19.1% |
| 2012 | 18.4% | -0.2% |
| 2011 | -11.0% | -13.6% |
| 2010 | 2.5% | -1.7% |
| 2009 | 33.9% | 22.2% |
| 2008 | -37.4% | -24.9% |
| 2007 | 6.2% | -5.5% |
| 2006 | 11.4% | 7.0% |
| 2005 | 4.3% | -16.8% |
| 2004 | -7.9% | -28.3% |
| 2003 | 29.0% | 5.7% |
| 2002 | -33.5% | -17.9% |
| 2001 | -10.1% | 2.0% |
| 2000 | 64.0% | -3.8% |
| 1999 | -13.3% | -19.6% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare DelCOL Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a DelCOL signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.